3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
5
Neoplasms
3
Fallopian Tube Neoplasms
3
Breast Neoplasms
3
Small Cell Lung Carcinoma
2
Prostatic Neoplasms
2
Carcinoma, Squamous Cell
2
Uterine Cervical Neoplasms
1
Urothelial Cancer
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Rectal Neoplasms
1
Pancreatic Adenocarcinoma
1
Oropharyngeal Neoplasms
1
Mouth Neoplasms
1
Lung Neoplasms
1
Laryngeal Diseases
1
Glioma
1
Carcinoma, Transitional Cell
1
Carcinoma
1
Anus Neoplasms
1
Advanced Solid Tumor, Adult
1
Advanced Solid Tumor
1
Interventions
pembrolizumab
17
Cisplatin
11
Carboplatin
9
Cyclophosphamide
8
fludarabine
6
Paclitaxel
6
Nivolumab
6
Bevacizumab
6
aldesleukin
5
Radiotherapy
5
toripalimab
4
tisotumab vedotin
4
fludarabine phosphate
4
Topotecan
4
Interleukin-2
4
Docetaxel
4
Brachytherapy
4
spartalizumab
3
Ipilimumab
3
Fulvestrant
3
ferumoxtran-10
2
enzalutamide
2
durvalumab
2
cemiplimab
2
bemarituzumab
2
balstilimab
2
Trastuzumab
2
Radiation
2
Magnetic Resonance Spectroscopy
2
Injections
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Uterine Cervical Neoplasms
×
niraparib
×
Clear all
NCT03644342
2024-09-03
NIVIX
Baylor College of Medicine
Phase 1/2
Terminated
4 enrolled
8 charts